

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
19 March 2020 (19.03.2020)



(10) International Publication Number  
**WO 2020/055943 A1**

(51) International Patent Classification:

*A61P 37/06* (2006.01) *A61K 39/395* (2006.01)  
*A61P 37/08* (2006.01) *A61K 39/00* (2006.01)  
*C07K 16/28* (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2019/050511

(22) International Filing Date:

11 September 2019 (11.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/731,204 14 September 2018 (14.09.2018) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly  
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **DEMAREST, Stephen John**; c/o Eli Lilly  
and Company, P.O. Box 6288, Indianapolis, Indiana  
46206-6288 (US). **KOESTER, Anja**; c/o Eli Lilly  
and Company, P.O. Box 6288, Indianapolis, Indiana  
46206-6288 (US). **MEHTA, Payal**; c/o Eli Lilly and Com-  
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288  
(US). **POTTER, Scott Charles**; c/o Eli Lilly and Compa-  
ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).  
**RUIZ, Diana Isabel**; c/o Eli Lilly and Company, P.O. Box  
6288, Indianapolis, Indiana 46206-6288 (US). **WITCHER,  
Derrick Ryan**; c/o Eli Lilly and Company, P.O. Box 6288,  
Indianapolis, Indiana 46206-6288 (US). **WU, Xiufeng**; c/o  
Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indi-  
ana 46206-6288 (US).

(74) Agent: **SHARP, Robert L.** et al.; c/o Eli Lilly and Compa-  
ny, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: CD200R AGONIST ANTIBODIES AND USES THEREOF

(57) Abstract: The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.



WO 2020/055943 A1